Literature DB >> 8807061

Genetic basis for clarithromycin resistance among isolates of Mycobacterium chelonae and Mycobacterium abscessus.

R J Wallace1, A Meier, B A Brown, Y Zhang, P Sander, G O Onyi, E C Böttger.   

Abstract

Resistance to clarithromycin among isolates of Mycobacterium chelonae and M. abscessus was observed in 18 of 800 (2.3%) patients tested between 1990 and 1995. Patients whose isolates were resistant had either disseminated disease or chronic lung disease, and the resistant isolates were recovered after clarithromycin monotherapy. Sequencing of the gene coding for the 23S rRNA peptidyltransferase region revealed a point mutation involving adenine at position 2058 (38%) or adenine at position 2059 (62%) in 20 of 20 relapse isolates from the first 13 patients identified. By pulsed-field gel electrophoresis or random amplified polymorphic DNA PCR, initial and relapse isolates were shown to have identical DNA patterns. M. chelonae and M. abscessus isolates were found to have only a single chromosomal copy of the rRNA operon, thus making them susceptible to single-step mutations. Thus, clarithromycin resistance in these species of rapidly growing mycobacteria relates to a point mutation in the gene coding for 23S rRNA and occurs in limited clinical situations, but was identified in almost 5% of isolates tested in 1995.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8807061      PMCID: PMC163394     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  32 in total

1.  Azithromycin for treatment of Mycobacterium avium-intracellulare complex infection in patients with AIDS.

Authors:  L S Young; L Wiviott; M Wu; P Kolonoski; R Bolan; C B Inderlied
Journal:  Lancet       Date:  1991-11-02       Impact factor: 79.321

2.  Mycobacteria possess a surprisingly small number of ribosomal RNA genes in relation to the size of their genome.

Authors:  H Bercovier; O Kafri; S Sela
Journal:  Biochem Biophys Res Commun       Date:  1986-05-14       Impact factor: 3.575

3.  Antimicrobial susceptibility of five subgroups of Mycobacterium fortuitum and Mycobacterium chelonae.

Authors:  J M Swenson; R J Wallace; V A Silcox; C Thornsberry
Journal:  Antimicrob Agents Chemother       Date:  1985-12       Impact factor: 5.191

4.  Mutations in 23S rRNA are associated with clarithromycin resistance in Helicobacter pylori.

Authors:  J Versalovic; D Shortridge; K Kibler; M V Griffy; J Beyer; R K Flamm; S K Tanaka; D Y Graham; M F Go
Journal:  Antimicrob Agents Chemother       Date:  1996-02       Impact factor: 5.191

5.  Mercuric reductase activity and evidence of broad-spectrum mercury resistance among clinical isolates of rapidly growing mycobacteria.

Authors:  V A Steingrube; R J Wallace; L C Steele; Y J Pang
Journal:  Antimicrob Agents Chemother       Date:  1991-05       Impact factor: 5.191

6.  Mutational resistance as the mechanism of acquired drug resistance to aminoglycosides and antibacterial agents in Mycobacterium fortuitum and Mycobacterium chelonei. Evidence is based on plasmid analysis, mutational frequencies, and aminoglycoside-modifying enzyme assays.

Authors:  R J Wallace; S I Hull; D G Bobey; K E Price; J M Swenson; L C Steele; L Christensen
Journal:  Am Rev Respir Dis       Date:  1985-08

7.  Activities of four macrolides, including clarithromycin, against Mycobacterium fortuitum, Mycobacterium chelonae, and M. chelonae-like organisms.

Authors:  B A Brown; R J Wallace; G O Onyi; V De Rosas; R J Wallace
Journal:  Antimicrob Agents Chemother       Date:  1992-01       Impact factor: 5.191

Review 8.  Spectrum of disease due to rapidly growing mycobacteria.

Authors:  R J Wallace; J M Swenson; V A Silcox; R C Good; J A Tschen; M S Stone
Journal:  Rev Infect Dis       Date:  1983 Jul-Aug

9.  Identification of clinically significant Mycobacterium fortuitum complex isolates.

Authors:  V A Silcox; R C Good; M M Floyd
Journal:  J Clin Microbiol       Date:  1981-12       Impact factor: 5.948

10.  Activities of clarithromycin against eight slowly growing species of nontuberculous mycobacteria, determined by using a broth microdilution MIC system.

Authors:  B A Brown; R J Wallace; G O Onyi
Journal:  Antimicrob Agents Chemother       Date:  1992-09       Impact factor: 5.191

View more
  95 in total

Review 1.  Macrolide resistance conferred by base substitutions in 23S rRNA.

Authors:  B Vester; S Douthwaite
Journal:  Antimicrob Agents Chemother       Date:  2001-01       Impact factor: 5.191

2.  Multisite reproducibility of Etest for susceptibility testing of Mycobacterium abscessus, Mycobacterium chelonae, and Mycobacterium fortuitum.

Authors:  G L Woods; J S Bergmann; F G Witebsky; G A Fahle; B Boulet; M Plaunt; B A Brown; R J Wallace; A Wanger
Journal:  J Clin Microbiol       Date:  2000-02       Impact factor: 5.948

3.  Clarithromycin resistance to Mycobacterium abscessus.

Authors:  B A Brown-Elliott; R J Wallace
Journal:  J Clin Microbiol       Date:  2001-07       Impact factor: 5.948

4.  Nontuberculous Mycobacterial Infections of the Lung.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  2000-06       Impact factor: 3.725

Review 5.  Antimicrobial susceptibility testing, drug resistance mechanisms, and therapy of infections with nontuberculous mycobacteria.

Authors:  Barbara A Brown-Elliott; Kevin A Nash; Richard J Wallace
Journal:  Clin Microbiol Rev       Date:  2012-07       Impact factor: 26.132

6.  Development of a real-time qPCR method for detection and enumeration of Mycobacterium spp. in surface water.

Authors:  Nicolas Radomski; Françoise S Lucas; Régis Moilleron; Emmanuelle Cambau; Sophie Haenn; Laurent Moulin
Journal:  Appl Environ Microbiol       Date:  2010-09-17       Impact factor: 4.792

7.  Mutations in 23S rRNA account for intrinsic resistance to macrolides in Mycoplasma hominis and Mycoplasma fermentans and for acquired resistance to macrolides in M. hominis.

Authors:  S Pereyre; P Gonzalez; B De Barbeyrac; A Darnige; H Renaudin; A Charron; S Raherison; C Bébéar; C M Bébéar
Journal:  Antimicrob Agents Chemother       Date:  2002-10       Impact factor: 5.191

8.  Comparison of in vitro activities of gatifloxacin and ciprofloxacin against four taxa of rapidly growing mycobacteria.

Authors:  Barbara A Brown-Elliott; Richard J Wallace; Christopher J Crist; Linda Mann; Rebecca W Wilson
Journal:  Antimicrob Agents Chemother       Date:  2002-10       Impact factor: 5.191

9.  A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae.

Authors:  Kevin A Nash; Barbara A Brown-Elliott; Richard J Wallace
Journal:  Antimicrob Agents Chemother       Date:  2009-01-26       Impact factor: 5.191

10.  Rapid molecular detection of inducible macrolide resistance in Mycobacterium chelonae and M. abscessus strains: a replacement for 14-day susceptibility testing?

Authors:  Kimberly E Hanson; E Susan Slechta; Haleina Muir; Adam P Barker
Journal:  J Clin Microbiol       Date:  2014-02-19       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.